Inicio › Linfoma de Burkitt › Kentucky
Ensayos clínicos de Linfoma de Burkitt en Kentucky
5 estudios sobre Linfoma de Burkitt buscan participantes en Kentucky.
Ciudades en Kentucky
Texto oficial del estudio (inglés)
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
ReclutandoFase 2
Edades de 1 a 30 · Todos los sexos · Actualizado el 12 nov 2026 · NCT04546399Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Kentucky/Markey Cancer Center, Lexington
ReclutandoFase 3
Edades de 18 a 39 · Todos los sexos · Actualizado el 3 nov 2026 · NCT03150693Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
ReclutandoFase 2
365 Days · Todos los sexos · Actualizado el 27 oct 2026 · NCT06317662A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
ReclutandoFase 2
366 Days – 46 Years · Todos los sexos · Actualizado el 27 oct 2026 · NCT06124157Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
ReclutandoFase 3
365 Days – 25 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT03959085De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.